DRUGDOCS®
@drugdocs.bsky.social
DRUGDOCS® provides health professionals with current best evidence on the drugs they prescribe with direct access to publications.
Ottawa, Canada | https://drugdocs.com/
Ottawa, Canada | https://drugdocs.com/
Top 3 drugs searched on DRUGDOCS® in November:
1. Tezspire®: Severe asthma biologic
2. Zolymbus®: Glaucoma eye treatment
3. Sovaldi®: Chronic hepatitis C antiviral
Explore the clinical evidence behind these drugs and more at drugdocs.com
#Pharma #DrugData #Asthma #Glaucoma #HepatitisC #DRUGDOCS
1. Tezspire®: Severe asthma biologic
2. Zolymbus®: Glaucoma eye treatment
3. Sovaldi®: Chronic hepatitis C antiviral
Explore the clinical evidence behind these drugs and more at drugdocs.com
#Pharma #DrugData #Asthma #Glaucoma #HepatitisC #DRUGDOCS
December 12, 2025 at 3:51 PM
Top 3 drugs searched on DRUGDOCS® in November:
1. Tezspire®: Severe asthma biologic
2. Zolymbus®: Glaucoma eye treatment
3. Sovaldi®: Chronic hepatitis C antiviral
Explore the clinical evidence behind these drugs and more at drugdocs.com
#Pharma #DrugData #Asthma #Glaucoma #HepatitisC #DRUGDOCS
1. Tezspire®: Severe asthma biologic
2. Zolymbus®: Glaucoma eye treatment
3. Sovaldi®: Chronic hepatitis C antiviral
Explore the clinical evidence behind these drugs and more at drugdocs.com
#Pharma #DrugData #Asthma #Glaucoma #HepatitisC #DRUGDOCS
@who.int issues its first global GLP-1 guideline for obesity, warning that by 2030 <10% of eligible people may have access.
💊 Find the clinical evidence for GLP-1 therapies at @drugdocs: drugdocs.com/search/GLP-1
🔗 Read more here: www.who.int/news/item/01...
#GLP1 #PublicHealth #DRUGDOCS
💊 Find the clinical evidence for GLP-1 therapies at @drugdocs: drugdocs.com/search/GLP-1
🔗 Read more here: www.who.int/news/item/01...
#GLP1 #PublicHealth #DRUGDOCS
December 8, 2025 at 4:23 PM
@who.int issues its first global GLP-1 guideline for obesity, warning that by 2030 <10% of eligible people may have access.
💊 Find the clinical evidence for GLP-1 therapies at @drugdocs: drugdocs.com/search/GLP-1
🔗 Read more here: www.who.int/news/item/01...
#GLP1 #PublicHealth #DRUGDOCS
💊 Find the clinical evidence for GLP-1 therapies at @drugdocs: drugdocs.com/search/GLP-1
🔗 Read more here: www.who.int/news/item/01...
#GLP1 #PublicHealth #DRUGDOCS
FDA approves HYRNUO® (sevabertinib) for adults with HER2 activating mutations in non-small cell lung cancer post-systemic therapy.
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
December 5, 2025 at 10:10 PM
FDA approves HYRNUO® (sevabertinib) for adults with HER2 activating mutations in non-small cell lung cancer post-systemic therapy.
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
It’s #CrohnsAndColitisAwarenessWeek (Dec 1–7).
Let’s raise awareness for the 10M+ people globally living with IBD.
💜 Understand the impact
💡 Share resources
🤝 Support the community
More info: crohnscolitisfoundation.org
#IBDAwareness #CCAwarenessWeek
@crohnscolitisfdn.bsky.social
Let’s raise awareness for the 10M+ people globally living with IBD.
💜 Understand the impact
💡 Share resources
🤝 Support the community
More info: crohnscolitisfoundation.org
#IBDAwareness #CCAwarenessWeek
@crohnscolitisfdn.bsky.social
December 3, 2025 at 2:42 PM
It’s #CrohnsAndColitisAwarenessWeek (Dec 1–7).
Let’s raise awareness for the 10M+ people globally living with IBD.
💜 Understand the impact
💡 Share resources
🤝 Support the community
More info: crohnscolitisfoundation.org
#IBDAwareness #CCAwarenessWeek
@crohnscolitisfdn.bsky.social
Let’s raise awareness for the 10M+ people globally living with IBD.
💜 Understand the impact
💡 Share resources
🤝 Support the community
More info: crohnscolitisfoundation.org
#IBDAwareness #CCAwarenessWeek
@crohnscolitisfdn.bsky.social
Dec 1 is #WorldAIDSDay, a moment to honour lives lost, support those living with HIV, and call for action to end AIDS.
This year’s theme, Overcoming Disruption, Transforming the AIDS Response, highlights the need for global solidarity, sustained investment, and action.
#EndAIDS #HIVAwareness
This year’s theme, Overcoming Disruption, Transforming the AIDS Response, highlights the need for global solidarity, sustained investment, and action.
#EndAIDS #HIVAwareness
December 1, 2025 at 7:37 PM
Dec 1 is #WorldAIDSDay, a moment to honour lives lost, support those living with HIV, and call for action to end AIDS.
This year’s theme, Overcoming Disruption, Transforming the AIDS Response, highlights the need for global solidarity, sustained investment, and action.
#EndAIDS #HIVAwareness
This year’s theme, Overcoming Disruption, Transforming the AIDS Response, highlights the need for global solidarity, sustained investment, and action.
#EndAIDS #HIVAwareness
Wishing you and your loved ones a restful, joyful, and abundant holiday season. 🦃🍂
Happy Thanksgiving from all of us at @drugdocs.bsky.social!
Happy Thanksgiving from all of us at @drugdocs.bsky.social!
November 28, 2025 at 1:55 AM
Wishing you and your loved ones a restful, joyful, and abundant holiday season. 🦃🍂
Happy Thanksgiving from all of us at @drugdocs.bsky.social!
Happy Thanksgiving from all of us at @drugdocs.bsky.social!
A Nature Medicine study finds that tirzepatide (Mounjaro/Zepbound) can silence the neural signature of “food noise,” offering the first direct look at how GLP-1 drugs affect the brain. This work could offer new opportunities for targeted therapies.
📰 Read the full article below.
📰 Read the full article below.
How obesity drugs quiet ‘food noise’ in the brain
Researchers have identified a neural biomarker of compulsive food cravings, and showed that it is suppressed by the weight-loss drug Mounjaro.
www.nature.com
November 24, 2025 at 5:54 PM
A Nature Medicine study finds that tirzepatide (Mounjaro/Zepbound) can silence the neural signature of “food noise,” offering the first direct look at how GLP-1 drugs affect the brain. This work could offer new opportunities for targeted therapies.
📰 Read the full article below.
📰 Read the full article below.
Today, on World Pancreatic Cancer Day, help raise awareness about the 6th leading cause of cancer death worldwide.
Early detection matters. Learn the symptoms: stomach or back pain, jaundice, weight loss. If they persist, talk to your doctor.
Join the global call to raise awareness this #WPCD💜
Early detection matters. Learn the symptoms: stomach or back pain, jaundice, weight loss. If they persist, talk to your doctor.
Join the global call to raise awareness this #WPCD💜
November 20, 2025 at 7:08 PM
Today, on World Pancreatic Cancer Day, help raise awareness about the 6th leading cause of cancer death worldwide.
Early detection matters. Learn the symptoms: stomach or back pain, jaundice, weight loss. If they persist, talk to your doctor.
Join the global call to raise awareness this #WPCD💜
Early detection matters. Learn the symptoms: stomach or back pain, jaundice, weight loss. If they persist, talk to your doctor.
Join the global call to raise awareness this #WPCD💜
New drugs to treat Alzheimer’s disease offer hope, but prevention still matters. A Nature Medicine study finds that taking 3,000-7,500 steps a day can slow cognitive decline by 3–7 years in people at risk. Even modest movement helps protect brain health. 🧠 Read more below.
Alzheimer’s decline slows with just a few thousand steps a day
A modest increase in physical activity can delay cognitive decline by three years — or more.
doi.org
November 18, 2025 at 3:32 PM
New drugs to treat Alzheimer’s disease offer hope, but prevention still matters. A Nature Medicine study finds that taking 3,000-7,500 steps a day can slow cognitive decline by 3–7 years in people at risk. Even modest movement helps protect brain health. 🧠 Read more below.
FDA approves #Blenrep (belantamab mafodotin-blmf) combo for relapsed/refractory multiple myeloma. DREAMM-7 showed improved survival vs comparator. REMS required due to ocular toxicity.
🔗 Read more: www.fda.gov/drugs/resour...
📄 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Blenrep
🔗 Read more: www.fda.gov/drugs/resour...
📄 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Blenrep
November 14, 2025 at 8:13 PM
FDA approves #Blenrep (belantamab mafodotin-blmf) combo for relapsed/refractory multiple myeloma. DREAMM-7 showed improved survival vs comparator. REMS required due to ocular toxicity.
🔗 Read more: www.fda.gov/drugs/resour...
📄 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Blenrep
🔗 Read more: www.fda.gov/drugs/resour...
📄 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Blenrep
It’s #WorldDiabetesDay, a day to raise awareness, improve access to care, and advance research in the fight against diabetes.
DRUGDOCS® gives you quick access to clinical evidence on treatments for diabetes, from insulin to SGLT2s & GLP-1s.
Start searching: drugdocs.com/search/diabe...
DRUGDOCS® gives you quick access to clinical evidence on treatments for diabetes, from insulin to SGLT2s & GLP-1s.
Start searching: drugdocs.com/search/diabe...
November 14, 2025 at 3:14 PM
It’s #WorldDiabetesDay, a day to raise awareness, improve access to care, and advance research in the fight against diabetes.
DRUGDOCS® gives you quick access to clinical evidence on treatments for diabetes, from insulin to SGLT2s & GLP-1s.
Start searching: drugdocs.com/search/diabe...
DRUGDOCS® gives you quick access to clinical evidence on treatments for diabetes, from insulin to SGLT2s & GLP-1s.
Start searching: drugdocs.com/search/diabe...
Top 3 drugs searched on DRUGDOCS® in October:
1. Hercessi® – HER2+ cancer biosimilar
2. Yervoy® – CTLA-4 inhibitor for cancer
3. Tyenne® – RA & GCA biosimilar
Explore the clinical evidence behind these drugs and more at drugdocs.com
#DrugDocs #Oncology #Biosimilars #PharmaData
1. Hercessi® – HER2+ cancer biosimilar
2. Yervoy® – CTLA-4 inhibitor for cancer
3. Tyenne® – RA & GCA biosimilar
Explore the clinical evidence behind these drugs and more at drugdocs.com
#DrugDocs #Oncology #Biosimilars #PharmaData
November 11, 2025 at 3:35 PM
Top 3 drugs searched on DRUGDOCS® in October:
1. Hercessi® – HER2+ cancer biosimilar
2. Yervoy® – CTLA-4 inhibitor for cancer
3. Tyenne® – RA & GCA biosimilar
Explore the clinical evidence behind these drugs and more at drugdocs.com
#DrugDocs #Oncology #Biosimilars #PharmaData
1. Hercessi® – HER2+ cancer biosimilar
2. Yervoy® – CTLA-4 inhibitor for cancer
3. Tyenne® – RA & GCA biosimilar
Explore the clinical evidence behind these drugs and more at drugdocs.com
#DrugDocs #Oncology #Biosimilars #PharmaData
Bayer’s Lynkuet (elinzanetant) has received FDA approval to treat moderate to severe vasomotor symptoms including hot flashes and night sweats, during menopause.
🔍 Explore the clinical evidence for Lynkuet at DRUGDOCS® drugdocs.com/drug/Lynkuet
#FDA #PharmaUpdate #MenopauseTreatment #DrugDocs
🔍 Explore the clinical evidence for Lynkuet at DRUGDOCS® drugdocs.com/drug/Lynkuet
#FDA #PharmaUpdate #MenopauseTreatment #DrugDocs
November 7, 2025 at 3:47 PM
Bayer’s Lynkuet (elinzanetant) has received FDA approval to treat moderate to severe vasomotor symptoms including hot flashes and night sweats, during menopause.
🔍 Explore the clinical evidence for Lynkuet at DRUGDOCS® drugdocs.com/drug/Lynkuet
#FDA #PharmaUpdate #MenopauseTreatment #DrugDocs
🔍 Explore the clinical evidence for Lynkuet at DRUGDOCS® drugdocs.com/drug/Lynkuet
#FDA #PharmaUpdate #MenopauseTreatment #DrugDocs
The FDA moves to speed up biosimilar approvals, aiming to lower costs and expand access to biologic treatments. The new draft guidance streamlines clinical requirements and encourages competition.
Read more and find the draft guidance here: www.fda.gov/news-events/...
#Biosimilars #FDA
Read more and find the draft guidance here: www.fda.gov/news-events/...
#Biosimilars #FDA
FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs
FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs
www.fda.gov
November 5, 2025 at 7:28 PM
The FDA moves to speed up biosimilar approvals, aiming to lower costs and expand access to biologic treatments. The new draft guidance streamlines clinical requirements and encourages competition.
Read more and find the draft guidance here: www.fda.gov/news-events/...
#Biosimilars #FDA
Read more and find the draft guidance here: www.fda.gov/news-events/...
#Biosimilars #FDA
It’s Movember, a reminder to prioritize men’s health and awareness for prostate & testicular cancer, mental health & suicide prevention.
This month, talk to your doctor & the men in your life, & donate to support research. Find information about men’s health & ways to support & join Movember below.
This month, talk to your doctor & the men in your life, & donate to support research. Find information about men’s health & ways to support & join Movember below.
November 3, 2025 at 7:05 PM
It’s Movember, a reminder to prioritize men’s health and awareness for prostate & testicular cancer, mental health & suicide prevention.
This month, talk to your doctor & the men in your life, & donate to support research. Find information about men’s health & ways to support & join Movember below.
This month, talk to your doctor & the men in your life, & donate to support research. Find information about men’s health & ways to support & join Movember below.
JAMA+ Women’s Health, a new hub for sex-specific evidence in every specialty, has launched!
At DRUGDOCS®, we believe data transparency fuels better decisions and it’s why our platform includes sex distribution data for every RCT, supporting transparency and equity in health research. drugdocs.com
At DRUGDOCS®, we believe data transparency fuels better decisions and it’s why our platform includes sex distribution data for every RCT, supporting transparency and equity in health research. drugdocs.com
October 30, 2025 at 5:46 PM
JAMA+ Women’s Health, a new hub for sex-specific evidence in every specialty, has launched!
At DRUGDOCS®, we believe data transparency fuels better decisions and it’s why our platform includes sex distribution data for every RCT, supporting transparency and equity in health research. drugdocs.com
At DRUGDOCS®, we believe data transparency fuels better decisions and it’s why our platform includes sex distribution data for every RCT, supporting transparency and equity in health research. drugdocs.com
On World Psoriasis Day, we join the National Psoriasis Foundation to raise awareness of psoriatic disease and its links to conditions like heart disease & diabetes. Take the first steps toward protecting your health @ www.psoriasis.org/world-psoriasis-day
World Psoriasis Day
Get ready for October 29 by learning about psoriasis and connecting with people who truly understand you.
www.psoriasis.org
October 29, 2025 at 8:07 PM
On World Psoriasis Day, we join the National Psoriasis Foundation to raise awareness of psoriatic disease and its links to conditions like heart disease & diabetes. Take the first steps toward protecting your health @ www.psoriasis.org/world-psoriasis-day
The FDA has approved Jascayd® (nerandomilast tablets), the first new treatment in mover than 10 years for idiopathic pulmonary fibrosis. Jascayd slowed lung function decline in trials, offering new hope for this serious, progressive disease.
🔬 Find the clinical data at DRUGDOCS.
🔬 Find the clinical data at DRUGDOCS.
DRUGDOCS | Jascayd®
drugdocs.com
October 23, 2025 at 1:47 PM
The FDA has approved Jascayd® (nerandomilast tablets), the first new treatment in mover than 10 years for idiopathic pulmonary fibrosis. Jascayd slowed lung function decline in trials, offering new hope for this serious, progressive disease.
🔬 Find the clinical data at DRUGDOCS.
🔬 Find the clinical data at DRUGDOCS.
FDA approves the Elecsys blood test to aid Alzheimer’s diagnosis. The test helps rule out the disease with 97.9% accuracy and may increase access to treatments like Leqembi and Kisunla.
📖 Read more below.
🔬 Explore the clinical data for Alzheimer’s drugs at DRUGDOCS: drugdocs.com/search/Alzhe...
📖 Read more below.
🔬 Explore the clinical data for Alzheimer’s drugs at DRUGDOCS: drugdocs.com/search/Alzhe...
www.reuters.com
October 21, 2025 at 5:32 PM
FDA approves the Elecsys blood test to aid Alzheimer’s diagnosis. The test helps rule out the disease with 97.9% accuracy and may increase access to treatments like Leqembi and Kisunla.
📖 Read more below.
🔬 Explore the clinical data for Alzheimer’s drugs at DRUGDOCS: drugdocs.com/search/Alzhe...
📖 Read more below.
🔬 Explore the clinical data for Alzheimer’s drugs at DRUGDOCS: drugdocs.com/search/Alzhe...
It's World Evidence-Based Health Care Day!
At DRUGDOCS®, the importance of using high-quality evidence to guide decisions that improve health outcomes is central to our work.
We’re proud to support this mission because informed prescribing starts with trusted information.
🔗 worldebhcday.org
At DRUGDOCS®, the importance of using high-quality evidence to guide decisions that improve health outcomes is central to our work.
We’re proud to support this mission because informed prescribing starts with trusted information.
🔗 worldebhcday.org
October 20, 2025 at 7:15 PM
It's World Evidence-Based Health Care Day!
At DRUGDOCS®, the importance of using high-quality evidence to guide decisions that improve health outcomes is central to our work.
We’re proud to support this mission because informed prescribing starts with trusted information.
🔗 worldebhcday.org
At DRUGDOCS®, the importance of using high-quality evidence to guide decisions that improve health outcomes is central to our work.
We’re proud to support this mission because informed prescribing starts with trusted information.
🔗 worldebhcday.org
New FDA approval: Palsonify (paltusotine) for acromegaly in adults who cannot undergo, or haven’t respond to, surgery.
56% achieved biochemical control in trials, a promising oral option for this rare disorder.
🔍Find the clinical data at drugdocs.com/drug/Palsoni...
#FDA #Acromegaly
56% achieved biochemical control in trials, a promising oral option for this rare disorder.
🔍Find the clinical data at drugdocs.com/drug/Palsoni...
#FDA #Acromegaly
October 16, 2025 at 7:06 PM
New FDA approval: Palsonify (paltusotine) for acromegaly in adults who cannot undergo, or haven’t respond to, surgery.
56% achieved biochemical control in trials, a promising oral option for this rare disorder.
🔍Find the clinical data at drugdocs.com/drug/Palsoni...
#FDA #Acromegaly
56% achieved biochemical control in trials, a promising oral option for this rare disorder.
🔍Find the clinical data at drugdocs.com/drug/Palsoni...
#FDA #Acromegaly
October marks Breast Cancer Awareness Month 🌸
This year’s focus at the #Global Breast Cancer Initiative: awareness, early detection, equitable access, and honoring those impacted.
Let’s turn awareness into action.
Find more information and how to get involved here: www.who.int/initiatives/...
This year’s focus at the #Global Breast Cancer Initiative: awareness, early detection, equitable access, and honoring those impacted.
Let’s turn awareness into action.
Find more information and how to get involved here: www.who.int/initiatives/...
The Global Breast Cancer Initiative
The World Health Organization’s Global Breast Cancer Initiative (GBCI), established in 2021, brings together stakeholders from around the world and across sectors with the joint goal of reducing globa...
www.who.int
October 15, 2025 at 5:47 PM
October marks Breast Cancer Awareness Month 🌸
This year’s focus at the #Global Breast Cancer Initiative: awareness, early detection, equitable access, and honoring those impacted.
Let’s turn awareness into action.
Find more information and how to get involved here: www.who.int/initiatives/...
This year’s focus at the #Global Breast Cancer Initiative: awareness, early detection, equitable access, and honoring those impacted.
Let’s turn awareness into action.
Find more information and how to get involved here: www.who.int/initiatives/...
FDA approves Vizz for presbyopia, a new use for an old glaucoma drug.
In clinical trials, Vizz was shown to improve near vision within 30 mins and lasts up to 10 hrs without affecting distance vision. A fresh option for millions dealing with age-related vision loss.
📖 Read more below.
In clinical trials, Vizz was shown to improve near vision within 30 mins and lasts up to 10 hrs without affecting distance vision. A fresh option for millions dealing with age-related vision loss.
📖 Read more below.
FDA grants first US approval for decades-old eye drug
Discover the world’s best science and medicine | Nature.com
www.nature.com
October 7, 2025 at 6:39 PM
FDA approves Vizz for presbyopia, a new use for an old glaucoma drug.
In clinical trials, Vizz was shown to improve near vision within 30 mins and lasts up to 10 hrs without affecting distance vision. A fresh option for millions dealing with age-related vision loss.
📖 Read more below.
In clinical trials, Vizz was shown to improve near vision within 30 mins and lasts up to 10 hrs without affecting distance vision. A fresh option for millions dealing with age-related vision loss.
📖 Read more below.
🔍 Top 3 most searched drugs on DRUGDOCS in September:
1️⃣ Tonmya – 1st non-opioid FDA-approved treatment for fibromyalgia since 2007
2️⃣ Harvoni – Antiviral with high cure rates for hepatitis C
3️⃣ Selarsdi – Biologic for plaque psoriasis and psoriatic arthritis
📖 Find the evidence @ drugdocs.com
1️⃣ Tonmya – 1st non-opioid FDA-approved treatment for fibromyalgia since 2007
2️⃣ Harvoni – Antiviral with high cure rates for hepatitis C
3️⃣ Selarsdi – Biologic for plaque psoriasis and psoriatic arthritis
📖 Find the evidence @ drugdocs.com
October 6, 2025 at 8:11 PM
🔍 Top 3 most searched drugs on DRUGDOCS in September:
1️⃣ Tonmya – 1st non-opioid FDA-approved treatment for fibromyalgia since 2007
2️⃣ Harvoni – Antiviral with high cure rates for hepatitis C
3️⃣ Selarsdi – Biologic for plaque psoriasis and psoriatic arthritis
📖 Find the evidence @ drugdocs.com
1️⃣ Tonmya – 1st non-opioid FDA-approved treatment for fibromyalgia since 2007
2️⃣ Harvoni – Antiviral with high cure rates for hepatitis C
3️⃣ Selarsdi – Biologic for plaque psoriasis and psoriatic arthritis
📖 Find the evidence @ drugdocs.com
